Community

Update as of 10 April: As written here in February, Delta is the leading carrier among the major US airlines and keeps that pole position even amidst the tariff-induced turmoil. True, the carrier had to jettison its record guidance for 2025 it had issued in January; still, Delta made a gross profit of roughly 1 cent per available seat mile in the traditionally weak winter quarter when other airlines struggle to turn any profit at all (my calculations from an adj.

Proximus: A Quiet Backup Plan Delivering 7% Gross Yield and Currency Upside The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside. Proximus currently offers investors a solid gross dividend yield of around 7%, translating to approximately 5% net return after typical 30% taxes.

Below is an analysis of West Red Lake Gold Mines Ltd. (TSXV: WRLG) assuming a successful restart of the Madsen mine and Rowan property, a precious metals bull market, and specific economic conditions.

RECENT PAST AGX has consistently delivered robust revenue growth, with fiscal year 2025 revenue rising 53% year-over-year to $874.2 million and net income surging 164% to $85.5 million. In recent quarters, revenue growth has exceeded 60% year-over-year, particularly fueled by performance in its Power Services segment.

Key Takeaways I believe the Canadian oil and gas sector is overlooked, mainly because of Donald Trump's upcoming second term. Regardless of Trump tariff risk, which I deem overblown due to economic recoil to the American Midwest, I believe Canadians have hedged their risk, improving exporting infrastructure.

The NLB Banka Vision: Achieving €2.2 Billion Revenue and €1 Billion Profit NLB Banka stands at a pivotal moment in its journey. Guided by a bold vision set forth by its Board of Directors, the bank is primed to transform into a leading financial powerhouse across Southeastern Europe (SEE).

1. Growth Engines in AI & Data Center AMD reported 36% YoY revenue growth in Q1 2025 , reaching $7.44B , with non‑GAAP EPS of $0.96 , a 55% YoY jump.

Key Takeaways Silo Pharma is advancing a diversified pipeline of innovative therapies aimed at major health challenges in Central Nervous System (CNS) disorders like PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis (MS). The company’s unique approach of combining traditional drugs with psychedelic-inspired therapies positions it to address significant gaps in the treatment landscape.

Boring, old, fusty SMSI eeking out an existence until the CEO throws in the towel. Ask these questions: What is the market potential for their latest software seeing that their main product is not available on all US networks, it's made for families, needed by one parent, who can be bothered to pay $10-20 (avg.) monthly for a software that their kids WON'T use - max 16m potential shoppers.